Bristol-Myers Squibb

Biogen Idec, WPI to develop programs for BETC

Friday, May 31, 2013 10:50 AM

Global biotechnology company Biogen Idec has signed a collaboration agreement with Worcester Polytechnic Institute (WPI) to develop and deliver programs at the university’s Biomanufacturing Education and Training Center (BETC) of Worcester, Mass.

More... »

Adaptive, BMS ink biomarker discovery collaboration agreement

Wednesday, May 15, 2013 11:57 AM

Adaptive Biotechnologies, a Seattle-based developer of next generation sequencing assays, has entered into a collaboration agreement with Bristol-Myers Squibb for the discovery of immunological biomarkers in oncology.

More... »

Ambrx, BMS collaborate on next-gen antibody drug conjugates

Monday, May 6, 2013 10:09 AM

Ambrx, a clinical stage biopharmaceutical company, entered into a collaboration agreement with Bristol-Myers Squibb for the discovery and development of novel antibody drug conjugates using Ambrx's protein medicinal chemistry technology.

More... »

David A. Dodd appointed president and CEO of Aeterna Zentaris

Friday, April 26, 2013 03:05 PM

Aeterna Zentaris, an oncology and endocrinology drug development company, has appointed David A. Dodd as president and CEO, succeeding Juergen Engel, PhD. Dodd has also been appointed director on the company's board of directors.

More... »

Merck, BMS to conduct phase II trial of MK-5172, daclatasvir for hep C

Monday, April 22, 2013 02:20 PM

Global healthcare company Merck has entered into a non-exclusive agreement with Bristol-Myers Squibb to conduct a phase II clinical trial to evaluate the safety and efficacy of a once-daily oral combination regimen consisting of BMS’s investigational NS5A replication complex inhibitor, daclatasvir, and Merck's investigational NS3/4A protease inhibitor, MK-5172, for the treatment of chronic hepatitis C virus (HCV) infection, genotype 1.

More... »

Santaris Pharma, BMS form discovery alliance for RNA-targeted medicines

Wednesday, April 17, 2013 09:44 AM

Santaris Pharma, a privately held biopharmaceutical company focused on disease-related mRNAs and microRNAs, has formed a worldwide strategic alliance with Bristol-Myers Squibb to discover and develop novel medicines using Santaris Pharma's proprietary Locked Nucleic Acid (LNA) Drug Platform.

More... »

BMS selects Quintiles as preferred central laboratory provider

Tuesday, April 16, 2013 10:06 AM

Quintiles, a provider of biopharmaceutical development and commercial outsourcing services, has been chosen as a preferred provider by Bristol-Myers Squibb to provide global support for BMS's central lab work, biomarker testing and assay development for the next five years.

More... »

BMS to spend $250M to expand biologics facility, create 350 jobs

Friday, April 12, 2013 10:43 AM

Bristol-Myers Squibb (BMS) is planning a $250 million expansion of its large-scale biologics manufacturing facility in Devens, Mass. The expansion will introduce biologics development and clinical trial manufacturing capabilities to the site, while adding approximately 350 employees to the Devens workforce over time.

More... »

BMS appoints Francis Cuss as executive vice president, CSO

Monday, April 8, 2013 03:00 PM

Bristol-Myers Squibb, a global biopharmaceutical company, has appointed Francis Cuss, MB, BChir, FRCP, as executive vice president and chief scientific officer, effective July 1 after Elliott Sigal, M.D., Ph.D., retires.

More... »

LabCorp Clinical Trials selected as preferred provider by BMS

Monday, April 8, 2013 11:05 AM

Laboratory Corporation of America Holdings (LabCorp) announced that LabCorp Clinical Trials has been selected as a preferred provider for full-service global central laboratory services and biomarker testing by Bristol-Myers Squibb.

More... »